Expression of biomarkers related with bone marrow cells in patients with acute myelogenous leukemia / 中国实验血液学杂志
Journal of Experimental Hematology
; (6): 1193-1198, 2014.
Article
in Chinese
| WPRIM (Western Pacific)
| ID: wpr-302321
Responsible library:
WPRO
ABSTRACT
This study was aimed to investigate the expression of biomarkers (PTEN, mTOR, NF-kB, CD44, PI3K) related with bone marrow cells in patients with acute myelogenous leukemia. The immunohistochemical method was used to detect the expression of PTEN, mTOR, NF-kB, CD44, PI3K in 20 patients. The AML patients were divided into remission group and non-remission group after calculating the percentage of leukemia cells in bone marrow. The results showed that by optical microscopy, the positive expression rates of PTEN, mTOR, NF-kB, CD44 and PI3K in remission group were 33.3%, 33.3%, 77.8%, 22.2%, 0, respectively; meanwhile, in non-remission group, the positive expression rates of above-menthioned biomarkers were 63.6%, 18.2, 90.9, 63.6%, 0, respectively. The percentage and mean OD for PTEN and CD44 were statistically different between the two groups (P < 0.05), but for mTOR, NF-kB and PI3K were not statistically differenly (P > 0.05). It is concluded that the high expression of PTEN and CD44 can be regarded as an important index for diagnosis and prognosis in acute myelogenous leukemia.
Full text:
Available
Health context:
SDG3 - Target 3.4 Reduce premature mortality due to noncommunicable diseases
Health problem:
Leukemia
/
Other Malignant Neoplasms
Database:
WPRIM (Western Pacific)
Main subject:
Prognosis
/
Bone Marrow Cells
/
Biomarkers
/
Leukemia, Myeloid, Acute
/
Chemistry
/
NF-kappa B
/
Phosphatidylinositol 3-Kinases
/
Diagnosis
/
PTEN Phosphohydrolase
/
TOR Serine-Threonine Kinases
Type of study:
Diagnostic study
/
Prognostic study
Limits:
Humans
Language:
Chinese
Journal:
Journal of Experimental Hematology
Year:
2014
Document type:
Article